Catalyst Event
Vertex Pharmaceuticals Inc (VRTX) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
6/1/2026, 12:00:00 AM
The U.S. FDA accepted Vertex's Biologics License Application (BLA) for povetacicept for the treatment of IgA nephropathy (IgAN) on June 1, 2026, granting it priority review. High importance is estimated due to the potential for >10% valuation impact from this major pipeline asset, with a PDUFA date of November 30, 2026, expected.
Korean Translation
미국 FDA, 2026년 6월 1일 IgA 신증(IgAN) 치료를 위한 포베타시셉트의 생물의약품 허가 신청(BLA)을 우선 심사 대상으로 접수함. 주요 신약의 우선 심사 승인에 따른 10% 이상의 기업 가치 상승이 예상되며, PDUFA 목표일은 2026년 11월 30일로 예정됨.
Related Recent Events
ON Semiconductor Corp (ON) · Other
Financial Analyst Day in New York City to provide updates on strategy and long-term financial plans is scheduled. Impact estimated at >=1% as analyst days usually provide incremental updates; the event is scheduled.
9/16/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart's Q2 FY2027 earnings release is scheduled.
8/20/2026, 12:00:00 AM
Lumentum Holdings Inc (LITE) · Earnings Release
Lumentum's next earnings release for Q4 2026 is scheduled for August 11, 2026; high importance as a primary volatility driver scheduled.
8/11/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
As quarterly results typically drive price movements exceeding 10% for major energy producers, the Q2 2026 earnings release on 2026-08-06 is scheduled.
8/6/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Kratos Defense & Security Solutions Inc (KTOS) · Earnings Release
Kratos is expected to announce its Q2 2026 earnings on 2026-08-06, with analysts forecasting an EPS of approximately $0.14. This event is estimated to have a ≥5% price impact and is scheduled.
8/6/2026, 12:00:00 AM